This may be one of the reasons for the limited anti-tumor effect of tirabrutinib in U-2932, and this finding was consistent with that of a previous study, which demonstrated that the contribution of AKT signaling to survival in U-2932 causes the low sensitivity to BTK inhibitors [69]. Here, AKT1 is linked to neoplasm.